Price movement over the last 24 hours
Arista Networks Inc vs Heron Therapeutics Inc — how do they compare? Arista Networks Inc trades at $187.85 (market cap $235.41B), while Heron Therapeutics Inc trades at $0.42 (market cap $79.52M). The key difference: Arista Networks Inc is far larger — about 2960.4× Heron Therapeutics Inc's market cap, and Arista Networks Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ANET | HRTX | |
|---|---|---|
Market Cap | $235.41B | $79.52M |
Sector | Technology | Health |
52-Week High | $186.96 | $2.18 |
52-Week Low | $107.37 | $0.39 |
Enterprise Value | $223.06B | $177.42M |
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $186.96, up 1.23% with strong technical momentum as price approaches resistance at $189. The company demonstrates robust fundamentals with 2025 revenue of $9.01B and net income of $3.51B (38.32% margin), though valuation metrics remain elevated with P/E of 64.25. Recent earnings beats and AI infrastructure tailwinds support positive sentiment.
Arista presents growth potential from AI networking demand with 75% analyst buy ratings and $192.82 consensus target, but faces risks from high valuation multiples and competitive pressures. The stock's technical setup suggests near-term resistance testing with support at $180, while fundamental strength supports long-term growth outlook.
HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.
The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.
Trailing returns across standard periods
Latest headlines on both assets
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →